MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition

Disclosures: Conflict-of-interest disclosure: S.R.D, E.J.O., and R.M.P. are employees of, and/or hold equity in, Epizyme, Inc.; S.R.D and E.J.O. hold a patent (US 8580762); S.A.A. has consulted for Epizyme, Inc.; all other authors declare no competing financial interests.

Contributions: M.W.M.K. performed experiments and wrote the manuscript; M.J.H. performed experiments and wrote the manuscript; S.R.D. performed experiments; R.P.K. performed ChIP-seq bioinformatic analysis; A.V.K. performed experiments; E.J.O performed experiments; J.E.B, M.A.C provided crucial research materials, analyzed and interpreted data, R.M.P. performed experiments and wrote the manuscript; S.A.A. designed the study, directed research and wrote the manuscript.